Mefloquine treatment for uncomplicated falciparum malaria in young children 6-24 months of age in northern Ghana. by Fryauff, David J et al.
Fryauff, DJ; Owusu-Agyei, S; Utz, G; Baird, JK; Koram, KA; Binka,
F; Nkrumah, F; Hoffman, SL (2007) Mefloquine treatment for un-
complicated falciparum malaria in young children 6-24 months of age
in northern Ghana. The American journal of tropical medicine and
hygiene, 76 (2). pp. 224-31. ISSN 0002-9637
Downloaded from: http://researchonline.lshtm.ac.uk/1319741/
DOI:
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Copyright the publishers
MEFLOQUINE TREATMENT FOR UNCOMPLICATED FALCIPARUM MALARIA IN
YOUNG CHILDREN 6–24 MONTHS OF AGE IN NORTHERN GHANA
DAVID J. FRYAUFF,* SETH OWUSU-AGYEI, GREGORY UTZ, J. KEVIN BAIRD, KWADWO A. KORAM,
FRED BINKA, FRANCIS NKRUMAH, AND STEPHEN L. HOFFMAN
US Naval Medical Research Unit No. 3, Cairo, Egypt; Navrongo Health Research Center, Navrongo, Upper East Region, Ghana;
Naval Medical Research Center, Silver Spring, Maryland; Noguchi Memorial Institute for Medical Research, University of Ghana,
Legon, Ghana; Department of Public Health and Epidemiology, School of Public Health, University of Ghana, Legon, Ghana
Abstract. Mefloquine (MQ) single dose 20 mg/kg treatment of falciparum malaria was evaluated in 186 children of
6–24 months of age in northern Ghana. There were 15 RII/RIII-type parasitologic failures, all with Day 2 MQ blood
levels significantly lower than children whose parasitemias cleared before Day 7 and remained clear through 28 days.
Predictors of RII/RIII parasitologic response were vomiting after MQ dosing, Day 2 MQ levels < 500 ng/mL, and
undetectable Day 2 levels of the carboxymefloquine metabolite. There were 50 cases of delayed RI parasitologic failure,
but 71% of these cases had undetectable Day 28 blood levels of MQ and drug levels in the remaining 29% ranged below
the 620 ng/mL level that suppresses MQ sensitive strains of P. falciparum. Drug levels among infants that tolerated MQ
well were not associated with age, weight, hemoglobin, parasitemia, and pre-existing symptoms of vomiting or diarrhea.
An observed recurrent parasitemia of 34,400 trophozoites/L against a MQ blood concentration of 550 ng/mL was taken
as indication of tolerance to suppressive levels of the drug at this location.
INTRODUCTION
Under the conditions of intense malaria transmission com-
monly seen throughout rural sub-Saharan Africa, Plasmo-
dium falciparum rapidly developed resistance to easily afford-
able drug treatments based on chloroquine or Fansidar.1,2
Consequently, mefloquine (MQ) became a sensible and
popular first-line drug for the prevention of malaria in trav-
elers, and where cost was not a primary limiting factor, this
drug was also considered a safe and effective single-dose
treatment of uncomplicated P. falciparum infection. How-
ever, despite limited and carefully supervised use of MQ in
combination with sulphadoxine and pyrimethamine (MSP),
treatment failure rates in Thailand rose 20-fold in just 4 years
and forced an abandonment of the MSP treatment strategy.3
In vitro tests from locations throughout Africa gave early
indication that even without prior exposure or drug pressure,
strains of malaria circulated that were inherently resistant to
MQ.4,5 The drug was 94% more effective than chloroquine
for preventing malaria among Peace Corps volunteers in
West Africa during 1992, but cases of MQ prophylaxis failure,
confirmed by high drug levels in blood (744–1,275 ng/mL),
have now been reported in African states ranging geographi-
cally from Tanzania to Sierra Leone.6,7 While the majority of
these have been isolated cases, spanning a dozen years, an
unexpectedly high MQ prophylaxis failure rate of 14% was
reported during 1998 at a single location in northern Ghana.8
This high prophylaxis failure rate was even more unusual
because it occurred among “malaria-immune” adult Ghana-
ians who had been randomized to receive standard weekly
dosing of MQ in a rigidly supervised double-blind, placebo-
controlled prophylaxis trial. This trial had been preceded in
1996 by studies of seasonal malaria incidence in young chil-
dren and against the likelihood of chloroquine and Fansidar
failures, MQ was the drug of choice selected for single dose
treatment of their uncomplicated malaria infections.9 We hy-
pothesized that a retrospective evaluation of the MQ treat-
ment outcomes in these non-immune children, and an analy-
sis of their MQ blood levels would be predictive of the MQ
prophylaxis failures that occurred among clinically-immune
adults in this same community 2 years later. In other words,
we sought details of recurrent parasitemias that occurred in
MQ-treated children, confirmation of dosing, and a determi-
nation of MQ levels in blood at the time of any early or late
treatment failures.
Because of cost and availability, MQ has not been widely
used for treatment in Africa, and taken collectively, trials of
MQ treatment in African children since the late 1980s have
not produced clear indications of either resistant infections or
successful treatments. A number of studies have reported that
young children tolerate single oral doses of the drug poorly,
leading some authorities to advise splitting the dose and to
guard against vomiting.10,11 Several studies have indicated
that diarrhea, either a preexisting condition or an adverse side
effect of the MQ therapy, is also associated with inadequate
MQ drug levels.12,13 In a study of infant children in French
Guyana pre-treated with metoclopramide before gastric tube
administration of a single 25 mg/kg dose of MQ, early vom-
iting occurred in 11.5%, and diarrhea was found to be the
most common adverse event of therapy.14 Host genetic fac-
tors, disease condition, and age have also been variably con-
sidered responsible for significant pharmacokinetic differ-
ences of MQ in whole blood and sera. In one comparative
study, healthy adult Swiss men achieved peak plasma MQ
levels 3-fold lower than parasitemic adult male Thais given
the same dose of MQ.15 Thai children 5–10 years of age
achieved a mean Day 2 blood level of 2,031 ng/mL that was
virtually the same as the mean serum level of 2,165 ng/mL
measured in Thai adults,3,16 but pharmacokinetic parameters
of Cmax and area under the curve (AUC) for MQ in Thai
infants with malaria were reported to be much higher than in
adult Thai patients.17 African children with malaria seem to
attain lower levels of MQ in blood, making treatments and in
vivo determinations of resistance problematic. Cohorts of
Malawian children younger than 5 years of age given single
15- or 25-mg/kg doses of MQ reportedly attained comparable
mean Day 2 blood levels of 1,043 and 1,420 ng/mL, respec-
tively, but mean levels in these young children by Day 7 fell
to 670 and 718 ng/mL, respectively, with individual measures
ranging from 26 to 1,716 ng/mL.10 Senegalese children > 1
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year old treated with a single oral dose of 12.5 mg/kg achieved
average Day 2 MQ and CMQ blood levels of 955 and 407
ng/mL, respectively.18 A more recent evaluation of the MQ
15-mg/kg single dose in young Malawian children reported a
mean Day 2 serum level of only 633 ng/mL.19 Given such
variables, uncertainties, and contradictions, we considered
that our provision of malaria therapy to Ghanaian infants
afforded an opportunity to broaden the knowledge base of
MQ treatment in the age and ethnic group at greatest risk of
infection, morbidity, and death by malaria.
MATERIALS AND METHODS
Study site. The Kassena Nankana District (KND), situated
in the Upper East Region of Ghana at its northern border
with Burkina Faso, is an administrative territory of 1,675 km2
with a population of ∼140,000 residents. The flat, open wood-
land ecology is termed Guinea Savannah, with annual rainfall
of ∼900 mm occurring from May to October. The ethnic Kas-
sem and Nankan tribes are predominantly subsistence farm-
ers cultivating seasonal millet; however, a dam constructed in
1980 provides irrigation for year-round rice and vegetable
cultivation for about one fifth of the district population. Ma-
laria is holoendemic, transmitted by Anopheles gambiae sensu
strictu, during the wet season and by An. funestus at a lower,
but continuous, rate across both seasons.20 The incidence of
malaria infection among young children was determined to be
9.1 infections per person-year during the wet season and 4.7
infections per person-year during the dry season.9 The MQ
treatment component of the dry season incidence study con-
stitutes the subject of this report.
Study subjects. Informed consenting parents enrolled their
children during November 1996 into a prospective study mea-
suring dry season malaria attack rates. Institutional boards of
the US Navy and the Ghanaian Ministry of Health conducted
ethical review and granted approval for the conduct of this
study. Approximately 28% of children screened were ex-
cluded, mainly because of severe anemia (hemoglobin [Hb] <
6.0 g/dL), and were referred for treatment. The enrolled dry
season cohort consisted of 259 breast-feeding children 6–24
months of age, all of whom received curative therapy consist-
ing of quinine sulfate (10 mg/kg orally, three times a day, days
1–4), Fansidar (5–10 kg, 1/2 tablet; 11–20 kg, 1 tablet; Day 5),
and primaquine (0.25 mg/kg orally, four times a day, days
5–18), except in the case of 17 glucose-6-phosphate dehydro-
genase–deficient children. All medications were given as sus-
pensions in a fruit-flavored sugar syrup. Children were visited
regularly, with blood films made every 2 weeks or at any
occasion of illness consistent with malaria (fever, chills, nau-
sea, vomiting, and malaise). The presence of asexual stages of
P. falciparum in a Giemsa-stained blood film prompted im-
mediate clinical evaluation and treatment. Uncomplicated
clinical malaria and parasitemias < 1% were treated with MQ.
Children averaged 6.9 (95% CI, 6.5, 7.3) parasite-free weeks
from the end of radical cure to re-infection and the initiation
of MQ treatment. Loss of premunition by the radical curative
therapy was thought responsible for significantly greater par-
asitemias in children at the time of reinfection.9
Chemotherapy. Mefloquine hydrochloride (Lariam; Hoff-
man-LaRoche, Basel, Switzerland) uncoated tablets contain-
ing 250 mg base were used to prepare a sweet syrup suspen-
sion containing 40 mg MQ base/mL. Children were given 0.5
mL of suspension/kg body weight (20 mg base/kg) as a one-
time oral dose administered by calibrated plastic syringe.
Each child was monitored thereafter for 1 hour, and dosing
was repeated if vomiting occurred. The 20-mg/kg body weight
dose selected was a compromise between intention to reduce
the likelihood of vomiting the dose in the young subjects and
intention to affect a full rapid cure. Children unable to toler-
ate MQ were treated with Fansidar or quinine.
Follow-up. Field workers conducted visits three times
weekly to monitor each child. Malaria blood smears were
made on days 0, 2, 7, and 28 or at any occasion of illness
consistent with malaria. Children who were symptomatic and
parasitemic were brought to the hospital for evaluation by a
physician. Children with unremitting or recurrent parasit-
emias during the MQ in vivo test were provided Fansidar or
quinine treatment. Heparinized capillary tubes were used to
collect 100 L of whole blood on days 2 and 28 or any day of
parasitemia that prompted alternative therapy. Capillary
blood was blotted onto a Whatman no. 2 filter paper that was
air-dried and thereafter kept refrigerated in separate plastic
ziplock bags. In the absence of evidence suggesting poor com-
pliance, emesis, or diarrhea at the time of dosing, parasitemias
that persisted or recurred within the 7 test days after MQ
treatment were classified according to World Health Organi-
zation (WHO) criteria as RII- or RIII-type resistance. Clear-
ance followed by recurrence of parasitemia between days 7
and 28 of the test represented either RI-type resistance or
re-infection.
Analysis of MQ levels in blood. Coded filter paper blood
blots were sent to the Department of Clinical Chemistry,
Falun Central Hospital, Falun, Sweden, where high-
performance liquid chromatography (HPLC) was used to de-
termine concentrations of MQ and its main metabolite, car-
boxymefloquine (CMQ).21 Sensitivity of this assay was 95
ng/mL (0.25 mol/L) for MQ and 75 ng/mL (0.20 mol/L) for
CMQ. It was reported that 5–10% degradation of MQ could
be expected from our handling of the samples before extrac-
tion and HPLC. Based on confirmed parasitemia, patient’s
illness and dosing history, concentrations of MQ in blood at
the time of parasitemia, and the threshold of 620 ng/mL (1.67
mol/L) blood concentration of MQ considered to be an ef-
fective barrier against the appearance of sensitive strains of P.
falciparum in the bloodstream,7,22 a determination of sensi-
tivity, resistance, or poor drug absorption was made.
Statistical analysis. Descriptive statistics were performed
for baseline characteristics of the enrolled children and their
parasitemias. Student t test was used to compare levels of MQ
and CMQ in cured cases and those considered early or late
treatment failures. 2 and Fisher exact tests were used to
compare proportions. Simple linear regression analysis was
used to explore the relationship between drug levels and vom-
iting or diarrhea. For graphing and statistical purposes, MQ
and CMQ values below the limits of detection were arbitrarily
assigned a value midway between that threshold value and
zero.
RESULTS
A total of 193 children with uncomplicated, slide-confirmed
falciparum malaria were evaluated and enrolled into the MQ
in vivo test. No symptoms were reported or observed for 29
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infants with parasitemias ranging from 40 to 26,000/L.
Among 164 infants with illness, fever was their dominant
symptom, reported by 81% of mothers. Additional symptoms
or conditions reported were chills/rigor (46%), diarrhea
(39%), vomiting (38%), apathy/listless (26%), respiratory ill-
ness (6.7%), and altered mental state (2%). Two cases were
excluded because of concomitant anti-malarial use, and five
individuals were lost to follow-up. Enrollment characteristics
of 186 children (Table 1) that were followed to an endpoint
show that anemia (Hb < 8.0 g/dL), measured fever (> 37.5°C),
and high-density parasitemia (> 20,000 asexual forms/L)
were conditions present in about one third of the children.
Therapy was supervised and directly observed in 98.7% of the
cases. Vomiting within the post-dosing observation period
and re-dosing occurred in 18 (9.3%) children.
Parasitemias cleared by Day 2 in 51% (93/181) and by Day
7 in 92% (170/185) of treated cases. Among 15 cases classified
as RII (9) and RIII (6) failures (Table 2) with persistent (13)
or recurrent, (2) parasitemias observed on or before Day 7,
records revealed histories of vomiting (3), diarrhea (2), or
both (4), emesis of the dose (2), and unmonitored dosing (1).
Geometric mean (GM) parasitemia for this group was 3,083/
L at the start of therapy and 349/L on Day 7. Figure 1A
shows that blood concentrations of MQ in these 15 cases
ranged on Day 2 from below detectable level to 350 ng/mL,
with a mean significantly below that of a random selection of
“sensitive” cases (Table 3) that cleared and remained clear
through the 28 day test period (RII/RIII: 172 ng/mL versus S:
561 ng/mL; P < 0.0001). Day 2 MQ and/or CMQ levels were
below the limits of detection in eight cases. There was no
apparent cause for early treatment failure among three chil-
dren with observed compliance and no record of vomiting or
diarrhea. Day 2 levels of MQ (210, 255, and 305 ng/mL) in
these exceptions, while being among the highest in this group,
were far below the lower 95% confidence limit of the drug in
whole blood (467 ng/mL) from children who were cured by
the treatment.
Late recurrent parasitemias ranging from 40 to 64,000/L
(GM, 10,560/L) developed in 50 children (50/186  27%).
Twelve of these cases were symptomatic and appeared be-
tween days 15 and 26. An additional 38 recurrent, but largely
asymptomatic, RI-type parasitemias were detected in the
scheduled Day 28 screen. MQ blood level analysis selected
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TABLE 1
Characteristics of the study population at enrollment
Characteristic Values
No. enrolled 186
Males:females 90:96
Mean age (mo) 15.51 (95% CI: 14.7–16.3)
Age range 6–25
Mean body weight (kg) 8.29 (95% CI: 8.1–8.5)
Mean hemoglobin (g/dL) 8.6 (95% CI: 8.3–8.8)
No. anemic (Hb < 8.0) 69 (37%)
Geometric mean (GM)
parasite density/L 3,363 (95% CI: 2,430–4,653)
No. febrile (%) 69 (37%)
GM parasite density
of febrile cases 8,670 (95% CI: 5,433–13,836)
GM parasite density
of non-febrile cases 2,138 (1,268–3,606)
No. parasitemias > 20,000/L 52 (28%)
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the 12 symptomatic cases and 12 others with parasitemias
> 6,680/L (Table 4). Day 2 levels of MQ > 500 ng/mL char-
acterized 33% of children with RI-type late recurrences com-
pared with 44% of children who remained clear through 28
days. Mean Day 2 drug and metabolite levels in these late
parasitemias were also lower, but not significantly different,
from that of sensitive cases (MQ:, 467RI versus 561S ng/mL;
P  0.28; CMQ: 220RI versus 229S ng/mL; P  0.90). Day 2
levels of MQ typically exceeded those of CMQ, averaging 2.6,
3.1, and 3.4 times higher in the RII/RIII, RI, and S groups,
respectively.
Day 2 levels of MQ < 500 ng/mL and Day 2 levels of CMQ
below the level of detection were both strongly associated
with vomiting after dosing (P < 0.0007) and RII/RIII (P <
0.001) parasitologic responses. There was a stronger negative
association on Day 2 between levels of CMQ and pre-
treatment vomiting (r  −0.41) than between MQ and vom-
iting (r −0.21). We found no association between mother’s
report at baseline of diarrhea in her child and Day 2 levels of
either MQ or CMQ. No association was seen between levels
of MQ or CMQ and parasitemia, age, weight, or hemoglobin.
Across all outcome groups, Day 28 MQ levels (Figure 1B;
Tables 2–4) were well below the putative boundary level of
FIGURE 1. Scatterplot of whole blood concentrations determined
for MQ and its carboxylic acid metabolite (CMQ) on days 2 (A) and
28 (B) after oral treatment with 20 mg/kg MQ base in young Gha-
naian children whose responses to treatment were classified as sen-
sitive (cure), delayed RI-type parasitologic failures, or RII/RIII early
parasitologic failure. The solid line at 620 ng/mL designates the MQ
blood concentration considered to be the threshold level required for
suppression of sensitive P. falciparum infections. This figure appears
in color at www.ajtmh.org.
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620 ng/mL needed to suppress susceptible strains of P. falci-
parum. Drug and/or metabolite levels were below the limits of
detection in 7 of the 16 “sensitive” cases and in 22 of the 24
late recurrent cases. Parent drug was more frequently de-
tected in sensitive cases than in RI cases (S: 56% versus RI:
22%; P  0.02), but mean MQ levels were not significantly
different in the two groups. The CMQ metabolite was more
often detected than MQ (40% versus 31%) and at concentra-
tions exceeding MQ in 17 of 29 cases (mean ratio of CMQ to
MQ: 1.4) where either parent drug or metabolite was mea-
surable.
One case of drug tolerance was documented in which a
parasitemia of 34,400/L on Day 28 was observed against an
MQ concentration of 550 ng/mL (1.46 mol/L). With a con-
ceivable 10% loss of MQ from this sample as a result of time
and storage conditions, the whole blood concentration at the
time of parasitemia may have been as high as 605 ng/mL, with
plasma levels even higher.
DISCUSSION
Apart from their critical need for malaria care during this
most vulnerable period in their lives, young children of 6–24
months of age are ideal for showing the effect of a drug,
alone, against malaria parasites and yield a valid in vivo test
outcome for drug resistance that is free from the confounding
effects of maternally and naturally acquired immunity. Lower
MQ failure rates in adults compared with young children have
been attributed to immunity, owing to comparable Day 2 drug
levels in the two groups.3 Our findings in this select popula-
tion of African infants yield no firm evidence of innate RII-
RIII resistance in the parasites and indicate that low drug
levels resulting from emesis, vomiting, poor absorption, and/
or incomplete dosing account for all of the 15 RII/RIII para-
sitologic responses that occurred. Based on the low levels of
MQ measured 48 hours after dosing in children who achieved
better treatment outcomes, we believe that re-infection, and
not late recrudescence, accounted for the majority of late
recurrent parasitemias seen. In the absence of molecular evi-
dence showing genotype differences between baseline and
recurrent parasitemias, additional support for this supposition
derives from the malaria incidence measured among these
same children immediately preceding their MQ treatment.
Assuming full compliance, normal absorption, and a normal
decline by Day 10 after receiving treatment to MQ blood
levels below the minimum inhibitory threshold of 620 ng/mL,
there would have been 3,078 child-days (∼8.4 child-years) of
re-infection risk leading up to the Day 28 endpoint of our MQ
in vivo test. From the calculated 4.7 infections per child-year
determined during that dry season,9 an expected 40 infections
would have occurred in our children. The difference between
the 50 late recurrent parasitemias observed and the 40 that
were expected is presumed to relate to less than ideal absorp-
tion of the drug and reduced sensitivity to MQ in a fraction of
the circulating P. falciparum strains.
Well before any use of MQ in Africa, P. falciparum strains
from Ghana and Ivory Coast showed tolerance to the highest
levels of MQ in the standard WHO in vitro micro-test.23 In
vitro test results from Senegal, Mali, Cameroon, and Nigeria
also gave indication of reduced sensitivity to MQ in the ab-
sence of direct pressure resulting from the use of that drug in
their populations.6 However, among the in vivo trials that
have followed, reasonable validation based on demonstration
of parasitemia and high levels of MQ in blood has only been
documented from Northern Cameroon.5 Two separate trials
of the 25-mg/kg dose in Nigerian children ranging from 6
months to 10 years of age reported 28-day cure rates of 93%
and 95%, respectively, both of which were supported by in
vitro measures of reduced MQ susceptibility, but neither were
validated by MQ blood levels at the time of recurrence.24,25 In
Northern Cameroon, among children 1–10 years of age, 13%
of cases showed persistent or rising parasitemias during the 7
days after MQ 25-mg/kg single dose treatment.5 Based on
Day 3 MQ levels > 500 nmol/L in these six children, RII-RIII
resistance to MQ was considered proven. In the absence of
prior MQ use in that area and supported by in vitro evidence,
investigators hypothesized MQ resistance in Northern Cam-
eroon to be a by-product of quinine resistance.5
Surprisingly, among Ghanaian children with good treat-
ment outcomes, the 20-mg/kg MQ dose did not seem to be
well absorbed, because Day 2 concentrations of drug > 500
ng/mL, a level associated with treatment success,5,10,12,18,19
were measured in only 33% of the children. Mefloquine is
rapidly absorbed, attains maximum blood levels within 24
hours of oral dosing, and concentrations of ∼1,000 ng/mL are
typically attained in older children and adults by the 25-mg/kg
treatment dose.26–28 Early treatment failures of MQ in
Malawian children were strongly associated with MQ blood
levels < 500 ng/mL on Day 2. These low Day 2 drug levels
were in turn associated with vomiting, which occurred in 40%
of children given a 15-mg/kg single dose and in 29% of those
who received a 25-mg/kg single dose. Surprisingly, among
children who did not vomit within 30 minutes of treatment,
Day 2 blood levels of MQ were comparable in both groups,
but 18% still had Day 2 MQ levels < 500 ng/mL. Because
unremitting or recurrent parasitemias developed within the
28-day test period in comparable proportions of low (62%)
and high (55%) dose groups, the authors refrained from any
interpretation of MQ resistance and called attention to the
problems of erratic drug absorption and vomiting in very
young children.19 In this regard, it seemed unusual that we
saw so few RII/RIII-type MQ failures in Ghanaian children,
and we suspect that parasitemias at that time and location
were relatively susceptible to the drug.
To date, the MQ prophylaxis failures that were reported
among adult Ghanaians have not been verified by drug levels
and may not have occurred in all cases by MQ-resistant para-
sites. Based on the low blood levels of MQ seen in their
children, wide inter-individual variation in MQ pharmacoki-
netics, low blood levels associated with lighter parasitemia,
older age, and ethnic/genetic factors, it seems possible that
the high failure rate of MQ prophylaxis in 6 of 46 Ghanaian
adults also resulted from poor drug absorption and inad-
equate blood levels.
Mefloquine performed poorly in Ghanaian infants, an age
group already prone to vomiting and diarrhea, and wide-
spread use of this drug, alone, for treatment of malaria may
exacerbate any existing low level resistance in the circulating
malaria. The mean Day 2 blood level of MQ we measured in
Ghanaian infants who tolerated MQ dosing well (mean: 501
ng/mL; 95% CI: 431–571; range: 170–1,005 ng/mL) was lower
than that reported for Senegalese (955 ± 74 ng/mL) or Mala-
wian (633 ± 343 ng/mL) children, and was grossly below
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the Cmax reported for Thai children (2,031 ± 831 ng/
mL).3,16,18,19,28 In retrospect of the globally low drug levels
achieved, we are also led to consider the possibility that our
formulating MQ as a suspension in a high-fructose, pine-
apple-flavored syrup may somehow have altered the drug’s
chemistry and/or subsequent bioavailability.
The carboxylic acid metabolite of MQ is inactive against
malaria but is deemed to have value in monitoring compli-
ance during prophylaxis.29 Our purpose in presenting CMQ
data for MQ-treated Ghanaian infants is that of verifying
drug consumption, providing an indication of the metabolism
of parent MQ in this relatively under-studied group and
showing its potential for predicting early treatment failures.
Great individual variability is typically seen in blood levels of
MQ and CMQ under both therapeutic and prophylactic regi-
mens, but pregnancy, parasitemia, and age are known deter-
minants of MQ absorption, distribution, and elimination.26–
28,30 Relevant to our findings in Ghanaian children are those
from Thailand which found that children 6–24 months of age
achieve peak levels, tissue distribution, and elimination of
MQ more rapidly than older children and adults.17 From this,
assuming a 12-hour peak in MQ blood levels, such as that
seen in young Thai children, our Day 2 measurement, 36
hours later, might be expected to show the heightened accu-
mulation of CMQ over MQ in Ghanaian children.31 This was
not apparent, however, and even at Day 28, we did not see
ratios of CMQ:MQ that approached those of 2–6 that have
been reported for adults on weekly prophylaxis.29,32 The
stronger negative correlation we observed on Day 2 between
CMQ levels and vomiting was noteworthy, and although our
study was not intended or powered to examine the relation-
ship between drug/metabolite levels and clinical condition of
these children, no correlation was seen between diarrhea at
baseline and blood levels of either MQ or CMQ measured on
Day 2. Multiple studies have reported an association between
diarrhea and low MQ drug levels in blood.11–14,16, Diarrhea,
anemia, and vomiting as conditions before MQ dosing were
not predictive of low Day 2 levels of MQ or treatment failure
in our Ghanaian children, but vomiting after the MQ dosing
observation period was clearly related to low drug levels and
early treatment failure.
In summary, a single oral dose treatment of a 20-mg/kg MQ
suspension to breast-feeding Ghanaian infants was well tol-
erated, but resulted in whole blood levels of the drug on Day
2 that were surprisingly low, even among those children that
had tolerated the suspension without vomiting. Early RII/
RIII-type parasitologic failures that occurred in 8% of the
infants were associated with vomiting after dosing, Day 2
blood levels of MQ < 500 ng/mL, and undetectable Day 2
levels of CMQ. Vomiting and diarrhea before dosing were
not associated with treatment failure. Despite no prior use of
MQ for treatment at this location, one instance was found of
reduced sensitivity by the parasite to this drug. Such early
evidence does provide some rationale and credence for mul-
tiple cases of MQ prophylaxis failure that occurred at the
same location 3 years later. Ghana thus joins a number of
other African nations that pose a risk to travelers of MQ
prophylaxis failure. We consider the collective results of this
study and others to be a warning against further use and/or
promotion of treatment by MQ alone for falciparum malaria
in this high transmission area of northern Ghana.
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